Carmen Cristescu *
* Dr. Carmen Cristescu, șef de lucrări, disciplina de Farmacologie, UMF Timișoara
Abstract
Among the varions anticancer drugs used alone or in combination during courses of chemotherapy anthracyclines (leader: doxorubicin) have greatly contributed to improve the prognosis of certain cancers. But their beneficial effect is impaired by an unquestionable toxicity notably for the heart. Changes in electrocardiograms, benign pericardial reactions may occur at an early stage of treatment. The cumulative toxicity of anthracyclines limits their use. The risk factors able to potentiate cardiotoxicity must be analysed before starting chemotherapy and follow up by echocardiography and isotope ejection fraction.